Share on StockTwits
 

Shares of Cadence Pharmaceuticals (NASDAQ:CADX) have been given a consensus recommendation of “Hold” by the eleven brokerages that are presently covering the stock, Analyst Ratings Network.com reports. Six analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 1-year price target among brokerages that have covered the stock in the last year is $9.79.

Shares of Cadence Pharmaceuticals (NASDAQ:CADX) opened at 13.98 on Monday. Cadence Pharmaceuticals has a 1-year low of $4.60 and a 1-year high of $14.24. The stock’s 50-day moving average is $11.61 and its 200-day moving average is $7.91. The company’s market cap is $1.203 billion.

A number of research firms have recently commented on CADX. Analysts at Guggenheim downgraded shares of Cadence Pharmaceuticals from a “buy” rating to a “neutral” rating in a research note on Friday, February 14th. They now have a $15.00 price target on the stock. Separately, analysts at Wedbush downgraded shares of Cadence Pharmaceuticals from an “outperform” rating to a “neutral” rating in a research note on Wednesday, February 12th. They now have a $14.00 price target on the stock, down previously from $15.00. Finally, analysts at Wedbush raised their price target on shares of Cadence Pharmaceuticals from $12.00 to $15.00 in a research note on Friday, January 17th.

Cadence Pharmaceuticals, Inc operates as a biopharmaceutical company. The Company focuses on the development and commercialization of therapeutics utilized primarily in the hospital setting.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.